Abdera Therapeutics
Paula Tao is an Associate Scientist at Abdera Therapeutics since December 2022, previously serving as a Research Associate at Zymeworks Inc. from January 2019 to December 2022, and has held roles as a Research Associate II and Research Associate I in the Antibody Discovery Group. Prior to Zymeworks, Paula worked as a Cooperative Education Student at Amgen in 2017, focusing on functional screening of antigen-specific antibodies, and at Kinexus in 2016, where projects included antibody purification and characterization. Paula holds a Bachelor of Science degree in Microbiology and Immunology from The University of British Columbia, completed in 2018.
Abdera Therapeutics
1 followers
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeuticand commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030.It was launched by adMare BioInnovations, Canada’s global life sciences venture, in partnership with industry leaders AbCellera, and some of the country’s most successful scientist entrepreneurs.